Table 3.
Clinical outcomes of non-diabetic patients with STEMI based on MAGE and ABG
| MAGE (mmol/L) | ABG (mmol/L) | |||||
|---|---|---|---|---|---|---|
| ≤3.26 | >3.26 | p | ≤7.80 | >7.80 | p | |
| n | 170 | 86 | 170 | 86 | ||
| Peak CK (U/L) | 905 (300–4077) | 1290 (471–4658) | 0.020 | 897 (300–4428) | 1372 (398–4658) | 0.039 |
| GRACE score | 140 ± 33 | 152 ± 34 | 0.005 | 141 ± 34 | 150 ± 33 | 0.036 |
| MACE | 20 (13.5) | 30 (31.4) | 0.001 | 26 (15.9) | 24 (26.7) | 0.046 |
| Cardiac death | 1 (0.6) | 5 (5.8) | 0.017 | 2 (1.2) | 4 (4.7) | 0.100 |
| New-onset MI | 3 (1.8) | 5 (5.8) | 0.123 | 4 (2.4) | 4 (4.7) | 0.448 |
| Acute HF | 4 (2.4) | 11 (12.8) | 0.001 | 7 (4.1) | 8 (9.3) | 0.156 |
| TVR | 12 (7.1) | 9 (10.5) | 0.346 | 13 (7.6) | 8 (9.3) | 0.637 |
Data are mean ± SD and number (%)
STEMI ST elevated myocardial infarction, MAGE the mean amplitude of glycemic excursions, ABG admission blood glucose, CK creatine kinase, MACE major adverse cardiac events, MI myocardial infarction, HF heart failure, TVR repeat target vessel revascularization